US Market Report for Cellular Allografts 2017 - MedCore

Wednesday, March 8, 2017 General News J E 4

LONDON, March 7, 2017 /PRNewswire/ -- DescriptionDownload the full report: Report Contents - Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends - Market Drivers & Limiters for each chapter segment - Competitive Analysis for each chapter segment - Section on recent mergers & acquisitions The cellular allograft market is segmented into usage for the cervical and lumbar regions of the spine. The cellular allograft market is the fastest growing within the overall bone graft market. By far, the largest market segment was for lumbar usage, with the remainder going to cervical. Both segments are growing rapidly, which will continue over the forecast period. Contributing to the larger market share of the lumbar segment is that much more graft material is required for lumbar usage. Use of stem cell grafts outside of the spine will also see growth; this should bring an even greater market potential for stem cell grafts. The high average selling price (ASP) of cellular allografts has provided incentives for new players to enter the market. The synergies between the bone graft substitute materials such as allografts and DBMs provide a platform for companies that operate within those markets to pursue growth by expanding into cellular allograft market. AbstractCellular allografts consist of allograft bone combined with adipose derived mesenchymal stem cells; or may refer to HCT/P (Human Cells, Tissues, and Cellular and Tissue-based Product) comprised of viable cells within a cortical cancellous bone matrix. The viable cell bone matrix (VCBM) is a cryopreserved cancellous bone combined with demineralized cortical bone matrix. Their key characteristic in regards to bone repair is that they provide osteogenic properties. Scope: 2013-2023Download the full report: ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith Research Advisor at Email: Tel: +44 208 816 85 48 Website:

To view the original version on PR Newswire, visit:

SOURCE ReportBuyer



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
US Market Report for Spinal Machined Bone Allograf...
Chronic Obstructive Pulmonary Disease - Heat Map a...